LB제약(LBRX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $41.50 (-1.52%), 시가총액 $0.85B, 52주 최저~최고 $14.61 ~ $32.88.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
LB제약의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
LB제약의 현재 주가는 $41.50 (-1.52%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
LB제약의 시가총액은 약 $0.85B입니다.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is